WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317862

CAS#: 76824-35-6

Description: Famotidine is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. Unlike cimetidine, the first H2 antagonist, Famotidine has no effect on the cytochrome P450 enzyme system and does not appear to interact with other drugs.

Price and Availability


USD 180
USD 350
USD 550
Ask price

USD 210
USD 400
USD 750
Ask price

USD 250
USD 450
USD 1150

Famotidine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 317862
Name: Famotidine
CAS#: 76824-35-6
Chemical Formula: C8H15N7O2S3
Exact Mass: 337.0449
Molecular Weight: 337.4454
Elemental Analysis: C, 28.47; H, 4.48; N, 29.06; O, 9.48; S, 28.51

Synonym: Famotidine, Famotidine Hydrochloride, MK-208, Pepcid, YM-11170, YM11170, YM 11170, MK 208, MK208

IUPAC/Chemical Name: (Z)-3-(((2-((diaminomethylene)amino)thiazol-4-yl)methyl)thio)-N'-sulfamoylpropanimidamide


InChi Code: InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

SMILES Code: N/C(N)=N\C1=NC(CSCC/C(N)=N/S(=O)(N)=O)=CS1

Technical Data

White to off-white solid powder.

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Lin SY. An overview of famotidine polymorphs: solid-state characteristics, thermodynamics, polymorphic transformation and quality control. Pharm Res. 2014 Jul;31(7):1619-31. doi: 10.1007/s11095-014-1323-5. Epub 2014 Mar 1. Review. PubMed PMID: 24577998.

2: Deeks ED. Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. Clin Drug Investig. 2013 Sep;33(9):689-97. doi: 10.1007/s40261-013-0113-x. Review. PubMed PMID: 23881568.

3: Schiff M, Peura D. HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol. 2012 Feb;6(1):25-35. doi: 10.1586/egh.11.88. Review. PubMed PMID: 22149579.

4: Tyre CC, Quan W. Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine. Clin J Oncol Nurs. 2007 Aug;11(4):513-9. Review. PubMed PMID: 17723964.

5: Martinez MC. Famotidine in the management of schizophrenia. Ann Pharmacother. 1999 Jun;33(6):742-7. Review. PubMed PMID: 10410190.

6: James LP, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin Pharmacokinet. 1996 Aug;31(2):103-10. Review. PubMed PMID: 8853932.

7: Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin Ther. 1996 Jan-Feb;18(1):36-54; discussion 35. Review. PubMed PMID: 8851452.

8: Golochevskaia VS. [Clinical aspects of Kvamatel (famotidine) administration]. Klin Med (Mosk). 1996;74(1):45-7. Review. Russian. PubMed PMID: 8649009.

9: Lengyel G, Fehér J. [Famotidine in the treatment of gastroduodenal ulcer]. Orv Hetil. 1994 Oct 16;135(42):2299-304. Review. Hungarian. PubMed PMID: 7970643.

10: Guimaraens D, Gonzales MA, Condé-Salazar L. Occupational allergic contact dermatitis from intermediate products in famotidine synthesis. Contact Dermatitis. 1994 Oct;31(4):259-60. Review. PubMed PMID: 7842684.

11: Yoshimoto K, Saima S, Echizen H, Nakamura Y, Kondo T, Yagishita Y, Ishizaki T. Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure. Clin Pharmacol Ther. 1994 Jun;55(6):693-700. Review. PubMed PMID: 8004885.

12: Wesdorp IC. Famotidine in gastroesophageal reflux disease (GERD). Hepatogastroenterology. 1992 Feb;39 Suppl 1:24-6. Review. PubMed PMID: 1577391.

13: Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991 Sep;21(3):178-94. Review. PubMed PMID: 1764869.

14: Grigor'ev PIa, Isakov VA, Iakovenko EP, Davydov SM, Vasil'eva ZI. [Famotidine--a new histamine H2 receptor blockader]. Klin Med (Mosk). 1991 Apr;69(4):23-8. Review. Russian. PubMed PMID: 1865643.

15: Dammann HG. Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview. Hepatogastroenterology. 1990 Jul;37 Suppl 1:2-5. Review. PubMed PMID: 2210612.

16: Langtry HD, Grant SM, Goa KL. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Oct;38(4):551-90. Review. PubMed PMID: 2573505.

17: Gitnick G. Famotidine in the USA: a review of efficacy studies. J Int Med Res. 1989;17 Suppl 1:17A-24A. Review. PubMed PMID: 2566539.

18: Berardi RR, Tankanow RM, Nostrant TT. Comparison of famotidine with cimetidine and ranitidine. Clin Pharm. 1988 Apr;7(4):271-84. Review. PubMed PMID: 2896559.

19: Mann SG. The place of famotidine in anti-ulcer therapy. Aliment Pharmacol Ther. 1987;1 Suppl 1:504S-509S. Review. PubMed PMID: 2979698.

20: Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol Suppl. 1987;134:55-60. Review. PubMed PMID: 2889260.